Journal of Clinical Oncology
Articles in this Issue
Effect of FDG-PET–based bone marrow assessment on prognostic accuracy compared to conventional histologic evaluation in patients with follicular lymphoma: A subanalysis of the FIL FOLL12 trial.
7074 Background: Bone marrow biopsy (BMB) is an invasive staging procedure for follicular lymphoma (FL) and its results ar...
Large language model-guided extraction of explainable clinical decision trees from longitudinal meningioma clinical notes.
e14004 Background: Meningiomas are the most common primary brain tumors, requiring longitudinal integration of clinical ob...
Retrospective assessment of Duffy-Null associated neutrophil counts (DANC) status and impact on treatment among patients with and without cancer in an urban academic medical center.
1642 Background: Duffy-Null Associated Neutrophil Count (DANC) is a non-pathologic state characterized by a low absolute n...
Global context matters: Vision transformer–based dermoscopic classification of skin tumors.
e13680 Background: Skin cancer is the most common malignancy worldwide, encompassing a spectrum from benign nevi to aggres...
Association between gut microbiome and treatment outcomes in metastatic pancreatic cancer patients: A pilot study.
e16381 Background: Pancreatic ductal adenocarcinoma (PDAC) remains a leading cause of cancer mortality in Japan, currently...
Long term survival outcomes of immune checkpoint inhibitors in metastatic melanoma: Later relapse and long-term outcomes beyond 5 years.
9556 Background: Immune checkpoint inhibitors (ICI) have improved survival outcomes in patients with metastatic melanoma,...
Developing early endpoints in neoadjuvant breast cancer to support accelerated approval.
e12755 Background: Pathologic complete response (pCR) is an early endpoint in neoadjuvant breast cancer considered in acce...
AI-driven H&E plasma cell to predict pathological complete response in IO-treated triple-negative breast cancer (Yale; NCT02489448).
1122 Background: Pathological complete response (pCR) remains difficult to predict in triple-negative breast cancer (TNBC)...
Camrelizumab (C) plus rivoceranib (R) with transarterial chemoembolization (TACE) vs TACE alone in unresectable hepatocellular carcinoma (uHCC): A randomized, phase 3 trial.
4001 Background: The combination of C (anti–PD-1 antibody) + R (VEGFR2 tyrosine kinase inhibitor) significantly improved p...
Chemotherapy use among women < 50 years with hormone receptor–positive breast cancer with low (≤15) Oncotype DX 21-gene recurrence score: A National Cancer Database (NCDB) analysis.
544 Background: RxPONDER demonstrated a benefit to chemotherapy (CT) in premenopausal women with hormone receptor-positive...
Clinical features, management, and outcomes of adolescents and young adults with myeloproliferative neoplasms.
6580 Background: Myeloproliferative neoplasms (MPNs)—polycythemia vera (PV), essential thrombocythemia (ET), myelofibrosis...
Survival in patients with hepatobiliary and pancreatic cancers taking GLP-1 receptor agonist therapy.
e16276 Background: Metabolic syndrome has been identified as an independent risk factor for hepatobiliary and pancreatic c...
Adenocarcinoma with cartilaginous and osseous metaplasia: A study of demographic and socioeconomic factors using the NCDB.
e12687 Background: Adenocarcinoma with cartilaginous and osseous metaplasia (ACOM) is a rare malignant tumor where gland-f...
Symptom profiles and cancer stage at diagnosis in gastroesophageal junction adenocarcinoma: An ordinal and clustering analysis.
e16005 Background: Gastroesophageal junction adenocarcinoma (GEJA) is often diagnosed at advanced stages, contributing to...
Reversible epigenetic control of CD146 phenotypic states in MDA-MB-231 breast cancer cells.
e13010 Background: Previous studies have demonstrated epigenetic regulation of the CD146...
Predicting fluoropyrimidine cardiotoxicity using a focus beyond routine cardiovascular risk assessment.
12030 Background: Fluoropyrimidines remain backbone of systemic therapy for colorectal cancer (CRC) but are associated wit...
Impact of travel distance on oncologic outcomes after curative-intent surgery for retroperitoneal sarcoma.
e23575 Background: Retroperitoneal sarcoma (RPS) is associated with high rates of recurrence despite optimal surgical mana...
Implementation of a multidisciplinary biomarker care pathway to reduce somatic sequencing failure rates in a community cancer center.
e23325 Background: Next-Generation Sequencing (NGS) of tumor DNA is critical for guiding targeted cancer therapies, but hi...
Preparedness of internal medicine residents for oncologic emergencies and end-of-life discussions in a community training environment.
9017 Background: Internal medicine (IM) residents often serve as first responders for patients with cancer in community ho...
Development of an [18F]-labeled glutamine PET radiotracer to detect serine synthesis pathway activity in HER2-positive breast cancer.
e15070 Background: Serine synthesis pathway (SSP) enzymes PSAT1 and PHGDH are highly upregulated in TP53-mutant breast can...
Age-centric insights: A single-center analysis of clinical presentation, treatment approaches, and outcomes in multiple myeloma patients across different age groups.
e19532 Background: Multiple myeloma (MM) accounts for approximately 10% of hematologic malignancies, with a rising inciden...
A phase 2 study of olutasidenib in combination with azacitidine followed by olutasidenib maintenance after venetoclax plus a hypomethylating agent regimen for <i>IDH1</i> -mutated acute myeloid leukemia (University of California Hematologic Malignancies Consortium Study 2441).
TPS6603 Background: Acute myeloid leukemia (AML) with isocitrate dehydrogenase-1 (IDH1) mutations represents a subset of u...
Impact of durvalumab treatment duration on survival and healthcare utilization after chemoradiation for lung cancer: A real-world analysis.
e20094 Background: Although durvalumab consolidation after chemoradiation improves survival in lung cancer, the ideal dura...
Prognostic impact of <i>PIK3CA</i> amplifications and co-occurring mutations detected through circulating tumor DNA (ctDNA) in metastatic breast cancer (MBC).
1036 Background: Activating PIK3CA mutations are established oncogenic drivers and...
Real-world comparative outcomes of first-generation versus second- and third-generation tyrosine kinase inhibitors in chronic myeloid leukemia: A global propensity-matched analysis.
e18595 Background: Second- and third-generation tyrosine kinase inhibitors (TKIs) are frequently used in chronic myeloid l...